-+ 0.00%
-+ 0.00%
-+ 0.00%

Abivax says Phase 3 ABTECT Maintenance Part 2 trial shows 37.2% remission with 50 mg obefazimod in refractory ulcerative colitis patients

PUBT·06/29/2026 20:05:51
Listen to the news
Abivax says Phase 3 ABTECT Maintenance Part 2 trial shows 37.2% remission with 50 mg obefazimod in refractory ulcerative colitis patients
  • Abivax released topline Phase 3 ABTECT Maintenance Part 2 results for oral obefazimod in moderately to severely active ulcerative colitis.
  • Continued treatment produced meaningful benefit in highly refractory patients, including some who failed to respond initially or relapsed on maintenance.
  • The added long-term safety data remained broadly consistent with expected ulcerative colitis background rates, supporting the program’s benefit-risk profile.
  • Results will be discussed in a conference call and webcast scheduled for later today.
  • Management kept its plan to file a U.S. NDA for obefazimod in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2356338_en) on June 29, 2026, and is solely responsible for the information contained therein.